Answers are grounded in this paper and cite their sources.
The present study aimed to assess the sensitivity of the Eastern Cooperative Oncology Group Performance Status (ECOG-PS) scale for scores other than 0 as a screening tool for sarcopenia in onco-hematology patients. A retrospective cohort study of 104 onco-hematology patients aged > 19 years and treated at the Diagnostic and Imaging Center and at an outpatient clinic of a private tertiary hospital was conducted. Sarcopenia was defined as a skeletal muscle index (SMI) of ≤ 38.5 cm2/m2 for women and ≤ 52.4 cm2/m2 for men based on positron emission tomography-computed tomography scans. Functional status was assessed using an ECOG-PS score of 0 (indicating no dysfunction) or a score of ≥ 1 (indicating dysfunction). Accuracy analysis was conducted to determine the sensitivity and specificity of the ECOG-PS as a screening tool for sarcopenia. Sarcopenia was observed in 57.7% of patients. The median SMI was 43.3 (55.1) kg/m2. Sarcopenia diagnosis was positively associated with male sex (p = 0.027) and an ECOG-PS score of ≥ 1 (p = 0.048). As a screening tool for sarcopenia, the ECOG-PS had sensitivity and specificity of 40.7% (95% confidence interval [CI] 30.6–50.8) and 83.8% (95% CI 75.1–92.9), respectively. Sarcopenia is a challenge in cancer. The association of sarcopenia with an ECOG-PS score of ≥ 1 observed in this study reinforces the study hypothesis and importance of further studies on the subject.
No takes yet. Share an insight, caveat, or question.
Guarnieri et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: